Edgen Stock·Oct 05 2025, 09:27戻る
戻る
Sanofi Stock Performance Reflects Strategic Realignment and Strong Dupixent Growth
Edgen Stock·Oct 05 2025, 09:27
[1] Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade) (NASDAQ:SNY) | Seeking Alpha (https://seekingalpha.com/article/4827905-sano ...)[2] Sanofi's investment strategy for transitioning to a pure biopharma - Labiotech.eu (https://vertexaisearch.cloud.google.com/groun ...)[3] Regeneron Reports Second Quarter 2025 Financial and Operating Results (https://vertexaisearch.cloud.google.com/groun ...)